Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Lipsitch

Showing results (371-380 of 446) with videos related to

Pageof 45
Sort By:
The New England Journal of Medicine|April 13, 2022
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide SettingOri Magen, Jacob G Waxman, Maya Makov-Assif, et al.
European Journal of Epidemiology|February 26, 2021
How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19Emma K Accorsi, Xueting Qiu, Eva Rumpler, et al.
Nature Communications|October 3, 2024
Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineageJoseph A Lewnard, Parag Mahale, Debbie Malden, et al.
BMC Infectious Diseases|July 21, 2010
Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009Edward Goldstein, Benjamin J Cowling, Justin J O'Hagan, et al.
Nature Genetics|June 11, 2013
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosisChristopher B Ford, Rupal R Shah, Midori Kato Maeda, et al.
The Lancet. Infectious Diseases|January 28, 2014
Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational studyYonatan H Grad, Robert D Kirkcaldy, David Trees, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineageJoseph A Lewnard, Parag Mahale, Debbie Malden, et al.
Science (New York, N.Y.)|June 23, 2012
Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis"Maria D Van Kerkhove, Steven Riley, Marc Lipsitch, et al.
Plos One|September 11, 2009
Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in MexicoMarc Lipsitch, Martin Lajous, Justin J O'Hagan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2003
Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infectionRichard Malley, Philipp Henneke, Sarah C Morse, et al.
Pageof 45

Showing results (371-380 of 446) with videos related to

Sort By:
Pageof 45
The New England Journal of Medicine|April 13, 2022
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide SettingOri Magen, Jacob G Waxman, Maya Makov-Assif, et al.
European Journal of Epidemiology|February 26, 2021
How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19Emma K Accorsi, Xueting Qiu, Eva Rumpler, et al.
Nature Communications|October 3, 2024
Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineageJoseph A Lewnard, Parag Mahale, Debbie Malden, et al.
BMC Infectious Diseases|July 21, 2010
Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009Edward Goldstein, Benjamin J Cowling, Justin J O'Hagan, et al.
Nature Genetics|June 11, 2013
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosisChristopher B Ford, Rupal R Shah, Midori Kato Maeda, et al.
The Lancet. Infectious Diseases|January 28, 2014
Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational studyYonatan H Grad, Robert D Kirkcaldy, David Trees, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineageJoseph A Lewnard, Parag Mahale, Debbie Malden, et al.
Science (New York, N.Y.)|June 23, 2012
Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis"Maria D Van Kerkhove, Steven Riley, Marc Lipsitch, et al.
Plos One|September 11, 2009
Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in MexicoMarc Lipsitch, Martin Lajous, Justin J O'Hagan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2003
Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infectionRichard Malley, Philipp Henneke, Sarah C Morse, et al.
Pageof 45